Valuation: Aprogen Biologics Inc.

Market Cap	27.4B 18.5M 16.17M 14.95M 13.72M 25.97M 1.78B 26.42M 178M 70.04M 870M 69.46M 67.93M 3B	P/E 2024	-0.79x	P/E 2025	-0.6x
Enterprise Value	205B 138M 121M 112M 102M 194M 13.31B 197M 1.33B 523M 6.5B 519M 507M 22.43B	EV / Sales 2024	3.66x	EV / Sales 2025	3.82x
Free-Float	95.86%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Aprogen Biologics Inc.

07-14	Aprogen Biologics Inc. announced that it expects to receive KRW 2.000000772 billion in funding from Aprogen, Inc.	CI
07-01	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-29	Aprogen Biologics Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
05-21	Aprogen Biologics Inc. announced that it expects to receive KRW 10 billion in funding from Aprogen, Inc.	CI
05-14	Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Aprogen Biologics Inc. announced that it has received KRW 2.000001375 billion in funding from Aprogen, Inc.	CI
04-13	Aprogen Biologics Inc. announced that it expects to receive KRW 2.000001375 billion in funding from Aprogen, Inc.	CI
03-20	Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-13	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
24/10/25	Aprogen Biologics Inc. announced that it has received KRW 15 billion in funding from APTN Inc.	CI
16/10/25	Aprogen Biologics Inc. announced that it expects to receive KRW 15 billion in funding from APTN Inc.	CI
13/08/25	Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
22/05/25	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

More news

News in other languages: Aprogen Biologics Inc.

23/11/20	MÄRKTE ASIEN/Kräftige Gewinne in Seoul und Schanghai - Tokio pausiert
23/11/20	MÄRKTE ASIEN/Aufwärts mit Impfstoff-Optimismus

More news

Managers and Directors: Aprogen Biologics Inc.

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	01/04/2012
Jae-Seob Kim CEO	Chief Executive Officer	63	13/10/2023
Jong-Soo Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Jae-Seob Kim BRD	Director/Board Member	63	13/10/2023
Jung-Chool Kim BRD	Director/Board Member	70	01/04/2012
Jong-Soo Kang BRD	Director/Board Member	62	-

More insiders

Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Employees

379

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/07/26	₩2,080.00	0.00%	71,517
15/07/26	₩2,080.00	+4.26%	56,623
14/07/26	₩1,995.00	+0.76%	45,712
13/07/26	₩1,980.00	-5.04%	68,646
10/07/26	₩2,085.00	+4.25%	46,532

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 16/07/2026			5-day change	1st Jan Change
2,080.00 ^KRW	0.00%		+5.96%	-73.28%

1 week	+5.96%
Current month	+0.73%
1 month	-18.91%
3 months	-44.75%
6 months	-72.32%
Current year	-73.28%

1 week	1,910	2,155
1 month	1,869	2,510
Current year	1,869	8,490
1 year	1,869	10,395
3 years	1,869	108,600
5 years	1,869	204,750
10 years	1,869	1,000,000

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/06/24	An-soo Kim	Fiscal year		2,188	0.0016%
28/06/24	Yun-Gyeong Bae	Fiscal year	Executive/Senior Manager	1,236	0.0009%
28/06/24	Yong-woo Kim	Fiscal year		1,070	0.0008%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APROGEN BIOLOGICS INC.	0.00%	+5.96%	-78.70%	-95.97%	18.39M
ELI LILLY AND COMPANY	+1.08%	-3.93%	+48.03%	+161.48%	1,031B
JOHNSON & JOHNSON	+1.19%	-3.52%	+51.70%	+57.14%	595B
ABBVIE INC.	+4.21%	+1.79%	+33.48%	+88.67%	431B
ROCHE HOLDING AG	+0.42%	-0.99%	+30.04%	+22.27%	326B
NOVARTIS AG	+1.03%	-2.10%	+28.32%	+45.08%	277B
ASTRAZENECA PLC	+0.49%	-11.32%	+20.31%	+22.32%	263B
NOVO NORDISK A/S	+1.59%	+3.91%	-22.47%	-36.84%	224B
AMGEN INC.	+3.70%	+2.19%	+24.27%	+63.09%	193B
GILEAD SCIENCES, INC.	+3.49%	+1.08%	+24.08%	+75.92%	164B
Average	+1.48%	-3.44%	+15.91%	+40.32%	350.43B
Weighted average by Cap.	+1.56%	-4.31%	+34.62%	+80.12%

Aprogen Biologics Inc. Stock

Stocks

A003060

KR7003060001

Pharmaceuticals

Valuation: Aprogen Biologics Inc.

Chart: Aprogen Biologics Inc.

Latest news : Aprogen Biologics Inc.

News in other languages: Aprogen Biologics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Aprogen Biologics Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

	2024	2025
Net sales	67.38B 45.49M 39.76M 36.77M 33.74M 63.86M 4.38B 64.97M 439M 172M 2.14B 171M 167M 7.39B	73.23B 49.43M 43.21M 39.96M 36.67M 69.4M 4.76B 70.61M 477M 187M 2.33B 186M 182M 8.03B
Net income	-105B -70.87M -61.95M -57.29M -52.57M -99.5M -6.83B -101M -683M -268M -3.33B -266M -260M -11.51B	-170B -115M -101M -92.95M -85.3M -161M -11.08B -164M -1.11B -435M -5.41B -432M -422M -18.68B
Net Debt	116B 78.11M 68.27M 63.14M 57.94M 110M 7.53B 112M 753M 296M 3.68B 293M 287M 12.69B	177B 120M 105M 96.68M 88.72M 168M 11.52B 171M 1.15B 453M 5.63B 449M 439M 19.43B